Lysogene скачать в хорошем качестве

Lysogene

Sean O’Bryan, VP, Regulatory Affairs and Quality Control Neuilly-sur-Seine, France (EURONEXT PARIS: LYS) Lysogene is a clinical-stage biotechnology company pioneering the basic research and clinical development of AAV gene therapy for CNS disorders with a high unmet medical need. Since 2009, Lysogene has established a solid platform and network with lead products in mucopolysaccharidosis type IIIA and GM1 gangliosidosis, to become a global leader in orphan CNS diseases. Neurological disorders such as MPS IIIA and GM1 require therapy to be broadly distributed throughout the brain. Since the blood brain barrier prevents efficient uptake of gene therapy vectors from the systemic circulation, Lysogene’s technology delivers vectors directly to the CNS. Lysogene has obtained orphan drug designation by the EMA and FDA and rare pediatric designation by the FDA for its MPS IIIA and GM1 programs. www.lysogene.com